MA23957A1 - Trihydrate de methanesulfonate de (1s,2s) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4- phenylpiperidine-1- yl-1- propanol et composition le contenant - Google Patents

Trihydrate de methanesulfonate de (1s,2s) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4- phenylpiperidine-1- yl-1- propanol et composition le contenant

Info

Publication number: MA23957A1
Authority: MA; Morocco
Prior art keywords: phenylpiperidine; hydroxyphenyl; propanol; hydroxy; composition containing
Prior art date: 1995-08-11

Application number

MA24335A

Other languages

English (en)

Inventor

Gene Sinay Terry

Maria Andino Marta

Fred Fiese Eugene

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-11

Filing date

1996-08-07

Publication date

1997-04-01

1996-08-07 Application filed by Pfizer filed Critical Pfizer

1997-04-01 Publication of MA23957A1 publication Critical patent/MA23957A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Virology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

MA24335A 1995-08-11 1996-08-07 Trihydrate de methanesulfonate de (1s,2s) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4- phenylpiperidine-1- yl-1- propanol et composition le contenant MA23957A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US223895P	1995-08-11	1995-08-11

Publications (1)

Publication Number	Publication Date
MA23957A1 true MA23957A1 (fr)	1997-04-01

Family

ID=21699847

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA24335A MA23957A1 (fr)	1995-08-11	1996-08-07	Trihydrate de methanesulfonate de (1s,2s) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4- phenylpiperidine-1- yl-1- propanol et composition le contenant

Country Status (41)

Country	Link
US (1)	US6008233A (fr)
EP (1)	EP0843661B1 (fr)
JP (1)	JP3099072B2 (fr)
KR (1)	KR100291882B1 (fr)
CN (2)	CN1615861A (fr)
AP (1)	AP755A (fr)
AR (1)	AR004676A1 (fr)
AT (1)	ATE215072T1 (fr)
AU (1)	AU710984B2 (fr)
BG (1)	BG63678B1 (fr)
BR (1)	BR9610766A (fr)
CA (1)	CA2228752C (fr)
CO (1)	CO4750830A1 (fr)
CZ (1)	CZ296236B6 (fr)
DE (1)	DE69620191T2 (fr)
DK (1)	DK0843661T3 (fr)
DZ (1)	DZ2083A1 (fr)
ES (1)	ES2170857T3 (fr)
GT (1)	GT199600051A (fr)
HR (1)	HRP960372B1 (fr)
HU (1)	HUP9802862A3 (fr)
IL (1)	IL122649A (fr)
IS (1)	IS1945B (fr)
MA (1)	MA23957A1 (fr)
NO (1)	NO310458B1 (fr)
NZ (1)	NZ309134A (fr)
OA (1)	OA10664A (fr)
PE (1)	PE4898A1 (fr)
PL (1)	PL185603B1 (fr)
PT (1)	PT843661E (fr)
RO (1)	RO120134B1 (fr)
RS (1)	RS49521B (fr)
RU (1)	RU2140910C1 (fr)
SA (1)	SA96170171B1 (fr)
SK (1)	SK284209B6 (fr)
TN (1)	TNSN96104A1 (fr)
TR (1)	TR199800208T1 (fr)
TW (1)	TW495502B (fr)
UA (1)	UA59341C2 (fr)
WO (1)	WO1997007098A1 (fr)
ZA (1)	ZA966760B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6046213A (en) *	1994-08-18	2000-04-04	Pfizer Inc.	Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives
EP0843661B1 (fr) *	1995-08-11	2002-03-27	Pfizer Inc.	Trihydrate de methanesulfonate de (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol
GB9820405D0 (en)	1998-09-18	1998-11-11	Smithkline Beecham Plc	Process
AU3676100A (en) *	1999-04-09	2000-11-14	Mochida Pharmaceutical Co., Ltd.	Remedies for neuropathic pain
GB9920917D0 (en)	1999-09-03	1999-11-10	Sb Pharmco Inc	Novel process
GB9920919D0 (en)	1999-09-03	1999-11-10	Sb Pharmco Inc	Novel compound
US6620830B2 (en) *	2000-04-21	2003-09-16	Pfizer, Inc.	Thyroid receptor ligands
YU27801A (sh)	2000-04-28	2003-04-30	Pfizer Products Inc.	Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
YU27701A (sh) *	2000-04-28	2003-04-30	Pfizer Products Inc.	Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
IL154378A0 (en)	2000-08-16	2003-09-17	Upjohn Co	Compounds for the treatment of addictive disorders
EP1186303A3 (fr) *	2000-09-06	2003-12-10	Pfizer Products Inc.	Combinaisons pharmaceutiques pour le traitement des accidents cerebrovasculaires, contenant un facteur inhibitant la neutrophile et un antagoniste selectif du NMDA-NR2B
EP1674087A1 (fr)	2000-10-02	2006-06-28	Pfizer Products Inc.	Utilisation prophylactique d'antagonistes des récepteurs du N-méthyl-D-aspartate (NMDA)
IL145584A0 (en)	2000-10-02	2002-06-30	Pfizer Prod Inc	Nmda nr2b antagonists for treatment
UA73619C2 (en) *	2000-12-13	2005-08-15	Pfizer Prod Inc	Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
JP4398247B2 (ja) *	2001-10-19	2010-01-13	富山化学工業株式会社	アルキルエーテル誘導体またはその塩
KR100517638B1 (ko)	2002-04-08	2005-09-28	주식회사 엘지생명과학	게미플록사신 산염의 새로운 제조방법
KR101052122B1 (ko)	2005-10-25	2011-07-26	시오노기세야쿠 가부시키가이샤	아미노디히드로티아진 유도체
EP2147914B1 (fr)	2007-04-24	2014-06-04	Shionogi&Co., Ltd.	Dérivés d'aminodihydrothiazine substitués par des groupes cycliques
EP2151435A4 (fr)	2007-04-24	2011-09-14	Shionogi & Co	Composition pharmaceutique pour le traitement de la maladie d'alzheimer
MX2010013256A (es)	2008-06-13	2010-12-21	Shionogi & Co	Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa.
JPWO2010047372A1 (ja)	2008-10-22	2012-03-22	塩野義製薬株式会社	Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
JPWO2011071135A1 (ja)	2009-12-11	2013-04-22	塩野義製薬株式会社	オキサジン誘導体
CA2816285A1 (fr)	2010-10-29	2012-05-03	Shionogi & Co., Ltd.	Derive de naphtyridine
EP2634188A4 (fr)	2010-10-29	2014-05-07	Shionogi & Co	Dérivé d'aminodihydropyrimidine fusionnée
TW201247635A (en)	2011-04-26	2012-12-01	Shionogi & Co	Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
JP2016501827A (ja)	2012-10-24	2016-01-21	塩野義製薬株式会社	Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
EP3194403B1 (fr)	2014-09-15	2019-02-06	Rugen Holdings (Cayman) Limited	Dérivés de pyrrolopyrimidine à titre d'antagonistes des récepteurs nmda nr2b
WO2016049048A1 (fr) *	2014-09-22	2016-03-31	Rugen Holdings (Cayman) Limited	Traitement des troubles de l'anxiété et des troubles du spectre autistique
US10221182B2 (en)	2015-02-04	2019-03-05	Rugen Holdings (Cayman) Limited	3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
US10584127B2 (en)	2015-06-01	2020-03-10	Rugen Holdings (Cayman) Limited	3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
US11000526B2 (en)	2016-11-22	2021-05-11	Rugen Holdings (Cayman) Limited	Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990014087A1 (fr) *	1989-05-17	1990-11-29	Pfizer Inc.	Derives de 2-piperidino-1-alcanol en tant qu'agents antiischemiques
US5272160A (en) *	1989-05-17	1993-12-21	Pfizer Inc	2-piperidino-1-alkanol derivatives as antiischemic agents
US6046213A (en) *	1994-08-18	2000-04-04	Pfizer Inc.	Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives
EP0843661B1 (fr) *	1995-08-11	2002-03-27	Pfizer Inc.	Trihydrate de methanesulfonate de (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol

1996
- 1996-06-20 EP EP96916266A patent/EP0843661B1/fr not_active Expired - Lifetime
- 1996-06-20 UA UA98020673A patent/UA59341C2/uk unknown
- 1996-06-20 BR BR9610766A patent/BR9610766A/pt not_active Application Discontinuation
- 1996-06-20 CZ CZ0039098A patent/CZ296236B6/cs not_active IP Right Cessation
- 1996-06-20 AU AU59084/96A patent/AU710984B2/en not_active Ceased
- 1996-06-20 KR KR1019980700989A patent/KR100291882B1/ko not_active Expired - Fee Related
- 1996-06-20 SK SK166-98A patent/SK284209B6/sk unknown
- 1996-06-20 CN CNA031584969A patent/CN1615861A/zh active Pending
- 1996-06-20 US US09/011,426 patent/US6008233A/en not_active Expired - Fee Related
- 1996-06-20 WO PCT/IB1996/000592 patent/WO1997007098A1/fr not_active Ceased
- 1996-06-20 TR TR1998/00208T patent/TR199800208T1/xx unknown
- 1996-06-20 JP JP09509083A patent/JP3099072B2/ja not_active Expired - Fee Related
- 1996-06-20 HU HU9802862A patent/HUP9802862A3/hu unknown
- 1996-06-20 ES ES96916266T patent/ES2170857T3/es not_active Expired - Lifetime
- 1996-06-20 RO RO98-00231A patent/RO120134B1/ro unknown
- 1996-06-20 PL PL96325050A patent/PL185603B1/pl not_active IP Right Cessation
- 1996-06-20 DK DK96916266T patent/DK0843661T3/da active
- 1996-06-20 PT PT96916266T patent/PT843661E/pt unknown
- 1996-06-20 DE DE69620191T patent/DE69620191T2/de not_active Expired - Fee Related
- 1996-06-20 IL IL12264996A patent/IL122649A/xx not_active IP Right Cessation
- 1996-06-20 AT AT96916266T patent/ATE215072T1/de not_active IP Right Cessation
- 1996-06-20 CN CN96195649A patent/CN1198739A/zh active Pending
- 1996-06-20 NZ NZ309134A patent/NZ309134A/en unknown
- 1996-06-20 RU RU98102116A patent/RU2140910C1/ru not_active IP Right Cessation
- 1996-06-20 CA CA002228752A patent/CA2228752C/fr not_active Expired - Fee Related
- 1996-06-24 TW TW085107571A patent/TW495502B/zh not_active IP Right Cessation
- 1996-07-04 GT GT199600051A patent/GT199600051A/es unknown
- 1996-07-23 SA SA96170171A patent/SA96170171B1/ar unknown
- 1996-08-06 PE PE1996000587A patent/PE4898A1/es not_active Application Discontinuation
- 1996-08-07 DZ DZ960127A patent/DZ2083A1/fr active
- 1996-08-07 MA MA24335A patent/MA23957A1/fr unknown
- 1996-08-07 TN TNTNSN96104A patent/TNSN96104A1/fr unknown
- 1996-08-07 AR ARP960103904A patent/AR004676A1/es unknown
- 1996-08-08 AP APAP/P/1996/000856A patent/AP755A/en active
- 1996-08-08 ZA ZA9606760A patent/ZA966760B/xx unknown
- 1996-08-09 HR HR960372A patent/HRP960372B1/xx not_active IP Right Cessation
- 1996-08-09 RS YU46196A patent/RS49521B/sr unknown
- 1996-08-09 CO CO96042164A patent/CO4750830A1/es unknown
1997
- 1997-12-30 IS IS4643A patent/IS1945B/is unknown
1998
- 1998-02-10 OA OA9800021A patent/OA10664A/en unknown
- 1998-02-10 NO NO19980574A patent/NO310458B1/no unknown
- 1998-02-27 BG BG102289A patent/BG63678B1/bg unknown

Also Published As

Publication number	Publication date
AU5908496A (en)	1997-03-12
CZ296236B6 (cs)	2006-02-15
KR100291882B1 (ko)	2001-10-26
TNSN96104A1 (fr)	2005-03-15
IL122649A0 (en)	1998-08-16
NO980574D0 (no)	1998-02-10
DK0843661T3 (da)	2002-07-22
CN1615861A (zh)	2005-05-18
BG102289A (en)	1998-09-30
NZ309134A (en)	1999-09-29
NO980574L (no)	1998-02-10
PL325050A1 (en)	1998-07-06
SK16698A3 (en)	1999-06-11
HRP960372A2 (en)	1998-04-30
WO1997007098A1 (fr)	1997-02-27
IS4643A (is)	1997-12-30
PL185603B1 (pl)	2003-06-30
ATE215072T1 (de)	2002-04-15
CN1198739A (zh)	1998-11-11
TW495502B (en)	2002-07-21
IL122649A (en)	2001-08-26
IS1945B (is)	2004-08-13
YU46196A (sh)	1999-07-28
RS49521B (sr)	2006-10-27
KR19990036321A (ko)	1999-05-25
RO120134B1 (ro)	2005-09-30
EP0843661B1 (fr)	2002-03-27
DE69620191D1 (de)	2002-05-02
EP0843661A1 (fr)	1998-05-27
HUP9802862A2 (hu)	1999-04-28
DE69620191T2 (de)	2002-07-18
CA2228752A1 (fr)	1997-02-27
SA96170171B1 (ar)	2006-05-20
JPH10510552A (ja)	1998-10-13
CO4750830A1 (es)	1999-03-31
CZ39098A3 (cs)	1999-02-17
PE4898A1 (es)	1998-03-16
DZ2083A1 (fr)	2002-10-23
AP755A (en)	1999-08-02
RU2140910C1 (ru)	1999-11-10
CA2228752C (fr)	2002-12-10
BR9610766A (pt)	1999-07-13
HUP9802862A3 (en)	1999-05-28
AR004676A1 (es)	1999-03-10
TR199800208T1 (fr)	1998-05-21
NO310458B1 (no)	2001-07-09
ES2170857T3 (es)	2002-08-16
AU710984B2 (en)	1999-10-07
HRP960372B1 (en)	2003-04-30
UA59341C2 (uk)	2003-09-15
MX9801149A (es)	1998-05-31
US6008233A (en)	1999-12-28
BG63678B1 (bg)	2002-09-30
OA10664A (en)	2000-11-06
ZA966760B (en)	1998-02-09
GT199600051A (es)	1997-12-26
PT843661E (pt)	2002-07-31
SK284209B6 (en)	2004-11-03
JP3099072B2 (ja)	2000-10-16
AP9600856A0 (en)	1996-10-31

Publication	Publication Date	Title
MA23957A1 (fr)	1997-04-01	Trihydrate de methanesulfonate de (1s,2s) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4- phenylpiperidine-1- yl-1- propanol et composition le contenant
MA24466A1 (fr)	1998-10-01	Compositions contenant de la tetrahydrolistatine
FR2740682B1 (fr)	1997-12-05	Composition topique contenant de la capsazepine
CY2005007I2 (el)	2009-11-04	Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
DE69418332D1 (de)	1999-06-10	Kosmetische zusammensetzung, die hydroxysaeuren enthaelt
DE69634053D1 (de)	2005-01-20	Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
DE69813826D1 (de)	2003-05-28	Kosmetische zusammensetzung die als verdickungsmittel siloxan-polyamide enthalten
HUP9801626A3 (en)	2000-06-28	Pharmaceutical composition containing proton pump inhibitors
ITRM960810A0 (it)	1996-11-27	Composizioni farmaceutiche contenenti ciclosporine o macrolidi
FR2781149B1 (fr)	2001-09-07	Composition deodorante contenant un sel d'alun
HUP9802999A3 (en)	1999-05-28	Pharmaceutical composition containing n-propargyl-1-aminoindan
PL317277A1 (en)	1997-06-09	Biaromatic compounds containing the adamantil group, pharmaceutic and cosmetic compositions containing them and their application
ATE240040T1 (de)	2003-05-15	Stabilisierte zusammensetzung, die halopropynyl- verbindungen enthält
ID17774A (id)	1998-01-29	Komposisi farmasi antitrombosis
PL317276A1 (en)	1997-06-09	Biaromatic compounds, pharmaceutic and cosmetic compositions containing them and their application
FR2737115B1 (fr)	1997-08-22	Composition stable contenant une enzyme
DE69911633D1 (de)	2003-10-30	Pharmazeutische zusammenstellungen die tetrahydroisoquinoleinverbindungen enthalten
DE69632237D1 (de)	2004-05-27	Kosmetische Zusammensetzungen enthaltend Tricholinecitrat
IT1292552B1 (it)	1999-02-08	Dispositivo per l'applicazione di rivestimenti.
FI973105L (fi)	1997-07-24	Menetelmä (4,10-diasetoksi-2alfa-bentsoyylioksi-5beta,20-epoksi,1,7beta-dihydroksi-9-oksotaks-11-en-13alfa-yyli)-(2R,3S)-3-bentsoyyliamino-3-fenyyli-2-hydroksipropionaattitrihydraatin valmistamiseksi
FI973229A0 (fi)	1997-08-05	Uusi farmaseuttinen koostumus
PT1017388E (pt)	2003-12-31	Composicao farmaceutica contendo ibuprofeno e domperidona para o tratamento de enxaqueca
TR199601012A2 (tr)	1997-06-21	Sampuan terkibi.
IT1298731B1 (it)	2000-02-02	Composizioni farmaceutiche contenenti complessi di inclusione con melatonina
FR2739382B1 (fr)	1997-11-14	Fraction ribosomale et composition la contenant